Ethiopia

in page functions
[French]
Ethiopia
Total population (2017) 104,344,587
Birth cohort (2017) 3,230,017
Surviving Infants (surviving to 1 year per year, 2017) 3,090,741
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 41/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 59/1000
World Bank Index, IDA (2015) 3.49
Gross Nation Income (per capita US$, 2015) 590
Co-financing group (2018) Initial self-financing
No. of districts/territories (2016) 840

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Ethiopia

Type of support

Approvals

2001-2022 (US$)
(29 May 2018)

Commitments

2001-2022 (US$)
(29 May 2018)

Disbursements

2000-2018 (US$)
(29 May 2018)

% Disbursed

(29 May 2018)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $965,148,345 $1,231,168,031 $953,837,242
Cash Support (CASHSUPP) $170,000 $195,000 $170,000 100%
Civil Society Organisation support (CSO) $3,320,000 $3,320,000 $3,420,000 103%
Cold Chain Equipment Optimisation Platform (CCEOP) $4,747,678 $20,875,664
Health system strengthening (HSS 1) $76,493,935 $76,493,935 $76,493,935 100%
Health system strengthening (HSS 2) $61,410,682 $61,410,682 $61,410,682 100%
Health system strengthening (HSS 3) $34,540,000 $80,590,000 $34,540,000 100%
HPV (NVS) $12,659,500 $40,478,500 $4,649,580 37%
HPV Demo (NVS) $147,439 $147,439 $147,439 100%
HPV MAC (NVS) $50,803,000 N/A
HPV MAC - Op costs (OPC) $4,195,200 N/A
Immunisation services support (ISS) $23,445,320 $23,445,320 $17,813,320 76%
Injection Safety Devices (NVS) $2,276,655 $5,626,155 $2,737,506 120%
Injection safety support (INS) $2,696,697 $2,696,697 $2,696,697 100%
IPV (NVS) $10,426,463 $10,426,463 $8,601,251 82%
Measles 1st and 2nd dose (NVS) $714,500 $1,954,500 $799,488 112%
Measles SIA (NVS) $8,458,031 $8,458,031 $8,458,031 100%
Measles SIA - Operational costs (OPC) $15,098,453 $15,098,453 $15,075,741 100%
Meningitis A - campaign (NVS) $43,030,647 $43,030,647 $44,310,479 103%
Meningitis A - operational costs (OPC) $37,949,808 $37,949,808 $34,028,741 90%
Penta (NVS) $236,504,887 $255,927,887 $235,828,690 100%
Pneumo (NVS) $309,645,911 $380,731,411 $325,426,535 105%
Rotavirus (NVS) $69,996,471 $95,897,971 $65,814,025 94%
Vaccine Introduction Grant (VIG) $11,415,268 $11,415,268 $11,415,102 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Ethiopia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 96%
M:F sex ratio at birth (2017) 1.04
Household survey: DTP3 coverage for male (2010) 34.30%
Household survey: DTP3 coverage for female (2010) 38.80%
Household survey: Last DTP3 survey (2010) 37%
% districts achieving > 80% DTP3 coverage (2016) 76%
% districts achieving < 50% DTP3 coverage (2016) 7%
MCV WHO/UNICEF estimates (2016) 70%

Breakdown of support

Non-vaccine support Vaccine support
27% 73%
$257,064,218 $696,773,024

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Ethiopia

19 May 2018

Kenya HPV

Gavi welcomes call for coordinated global action against cervical cancer

Alliance pledges to continue support for vaccines.

09 January 2018

IFFIm Chair - René Karsenti and Cyrus Ardalan

Cyrus Ardalan becomes new Chair of IFFIm Board

Ardalan succeeds René Karsenti, who oversaw nearly US$ 2.5 billion in bond issuances, entry into Sukuk markets.

26 October 2017

Malawi MR 2017
close icon

modal window here